Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

MUC1 immunotherapy

(2010) Richard E Beatson et al.   Immunotherapy

Differential Induction of Innate Immune Responses by Synthetic Lipid A Derivatives

(2010) Jidnyasa Gaekwad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model

(2009) S Julien et al.   BRITISH JOURNAL OF CANCER

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells

(2008) P. A. Cohen et al.   BLOOD

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes

(2008) Tanja Ninkovic et al.   MOLECULAR IMMUNOLOGY

Mucin-type O-glycosylation and its potential use in drug and vaccine development

(2007) Mads Agervig Tarp et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS